20th European Congress on Alternatives to Animal Testing, August 24-27 2016, University of Linz, Austria

Oral presentations by sessions

(vers. 19.08.2016)

Download the abstractbook here (higher resolution, 55 mb). Or with a lower resolution here (3 mb).

K1 Opening & Keynote Lecture I (plenary)
Wednesday, 24 August 2016
    Welcome addresses
15 min   25th Anniversary of the European Congresses on Alternatives to Animal Testing in Linz, Austria
Horst Spielmann, DE-Berlin
30 min   The 3Rs in relation to REACH
Derek Knight, FI-Helsinki
K2 Keynote Lecture II (plenary)
Thursday, 25 August 2016
30 min   Real world medicine and real world patients: Something that animal testing can never approximate
Michael Liebmann, US-Kennett Square
K3 Keynote Lecture III (plenary)
Friday, 26 August 2016
30 min   Combating infectious diseases, novel approaches and in vitro models
Claus-Michael Lehr, DE-Saarbruecken
K4 Keynote Lecture IV (plenary)
Saturday, 27 August 2016
30 min   The CRISPR/Cas9 sytstem: a game changer in the life sciences
Malte Spielmann, DE-Berlin
1 EU 3Rs Projects in Toxicology & other 3Rs Funding Institutions
Wednesday, 24 August 2016
30 min   SEURAT-1: A cluster of European projects that have changed the landscape for 21st century European toxicology
Andrea-Nicole Richarz, IT-Ispra
30 min   The EU-ToxRisk project: A European flagship program for mechanism-based safety sciences and risk assessment
Mardas Daneshian, DE-Konstanz
15 min   The Lush Prize - an overview
Rebecca Ram, UK-Manchester
15 min   A retrospective on 40 years of funding animalfree methods
Stefanie Schindler, CH-Bern
2 Global Cooperation on Implementing the 3Rs
Wednesday, 24 August 2016
20 min   The current status of non-animal test methods and prospects for Asian cooperation
Hajime Kojima, JP-Tokyo
20 min   The current status of nonanimal alternatives in the life sciences in China
Mao Ling Wei, CN-Chengdu
20 min   Examination of the gap between validation and (real) regulatory acceptance
Erin Hill, US-Gaithersburg
15 min   Norecopa: providing global 3R-resources for animal research
Adrian Smith, NO-Oslo
15 min   MAD world? Promoting the greater mutual acceptance of data
Jarlath Hynes, BE-Brussels
paid advertising

Banner InSphero

3 Ethical and Legal Issues
Thursday, 25 August 2016
15 min   An ethical challenge to the normalisation of animal experimentation
Kay Peggs, UK-Winchester
15 min   A proposal for a catalogue of criteria to objectify the harm-benefit analysis of proposed projects including animal experiments
Norbert Alzmann, DR-Tuebingen
15 min   Applying the harm benefit assessment under the EU Directive – what does it mean in practice for animals?
Katy Taylor, UK-London
15 min   Biotechnological chimeras and experimentation: legislative lacunae legerdemain?
Maureen O'Sullivan, IR-Galway
15 min   Ethical aspects of the Crispr/Cas9 technology
Henriette Bout, NL-Amsterdam
15 min   Non-human primates in neuroscience research: Can it be ethical, if it isn’t scientifically necessary?
Jarrod Bailey, UK-London
4 Implementing Dir 2010/63/EU
Thursday, 25 August 2016
20 min   The role of the National Committees (NC) and Animal Welfare Bodies (AWB) under Directive 2010/63/EU
Susanna Louhimies, BE-Brussels
15 min   Towards a harmonized approach: Role of the German National Committee for the Protection of Animals Used for Scientific Purposes in the process of implementation of the Directive 2010/63/EU
Justyna Chmielewska, DE-Berlin
15 min   Role of the Swedish national committee in the harmonization of project authorization and evaluation
Katarina Cvek, SE-Uppsala
15 min   Establishing a culture of care by implementing AUGUST – a new and strong initiative at Aarhus University
Birgitte Kousholt, DK-Aarhus N
15 min   From the guideline to the bench – The role of science based policy advice in implementing EU Dir 63/2010 in Germany
Henning Steinicke, DE-Halle
15 min   Animal welfare requirements – significant room for improvement
Irmela Ruhdel
, DE-Neubiberg
5.1 Novel Approaches in Efficacy and Safety Testing – 3D models I
Thursday, 25 August 2016
20 min   A three-dimensional bioprinted liver equivalent for human-on-a-chip toxicity screenings
Tobias Grix, DE-Berlin
20 min   Studying liver toxicity and disease modelling using bioprinted 3D human liver tissue
Christine Daly, UK-London
20 min   Hepatic differentiation of hiPSC in co-culture with endothelial cells using different culture media
Nora Freyer, DE-Berlin
15 min   In vitro study of melatonin effect on HepG2 cells treated with IL-6 in newly developed liver on chip device
Mi Jang, DE-Saarbruecken
15 min   A modular cell sheet-based approach towards 3D tissue models
Marie Weinhart, DE-Berlin
5.2 Novel Approaches in Efficacy and Safety Testing – 3D models II
Thursday, 25 August 2016
25 min   OncoCilAir™: Organotypic human in vitro model for lung cancer research
Samuel Constant, CH-Plan-les-Ouates
20 min   Migrating to the 3rd dimension: the “Neurosphere Assay” to study migration disturbances during neurodevelopment
Marta Barenys, DE-Duesseldorf
20 min   The 'Neurosphere Assay' as a valuable part of a DNT testing strategy
Ellen Fritsche, DE-Duesseldorf
20 min   ATERA: advanced 3D human tissue models and exclusive testing services for cosmetic, consumer product and pharmaceutical industry
Bart De Wever, LU-Esch-sur-Alzette
5.3 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips I
Friday, 26 August 2016
20 min   From organoid technology to Multi-Organ-Chip development for substance testing
Mark Rosowski, DE-Berlin
20 min   Increasing biological relevance in vitro: From single microtissues to micro-physiological systems
Jens Kelm, CH-Zurich
20 min   Creating organotypic oxygen tension in cell culture chambers using perfused flow and flexible chamber geometry
Kelly Davidge, UK-Rotherham
15 min   Online TEER measurements in Homunculus system for orally administered drugs testing
Dmitry Sakharov, RU-Moscow
15 min   Utilization of Hommunculus platform for evaluation of cytochrome P450 activity in "liver-on-a-chip"
Andrey Poloznikov, RU-Moscow
5.4 Novel Approaches in Efficacy and Safety Testing – Multi-Organ-Chips II
Friday, 26 August 2016
20 min   Bringing a human heart & fat on a chip: microphysiological platforms as in vitro models of cardiac and adipose tissue
Peter Loskill, DE-Stuttgart
20 min   High-throughput microfluidic platform for culture of 3D-kidney tissue models
Henriëtte Lanz, NL-Leiden
20 min   Towards lung disease-on-chip models and personalized medicine application
Colette Bichsel, CH-Bern
15 min   Vascularization of Multi-Organ-Chips for tissue engineering and regenerative medicine
Severin Mühleder, AT-Vienna
15 min   Opportunities for Organ-on-a-Chip models in toxicological risk assessment
Minne Heringa, NL-Bilthoven
paid advertising

Banner TissUse

6.1 Stem Cells & Reproductive Toxicity (including mEST & hEST) - Stem Cells
Thursday, 25 August 2016
20 min   Cardiotoxicity gene and miRNA biomarkers induced by anticancer drugs
Agapios Sachinidis, DE-Cologne
20 min   Practical application of human iPS cells for chemical toxicity assessment
Yasunari Kanda, JP-Tokyo
20 min   A hiPSC-based test platform (DropTech®) for toxicity assessment of small molecule compounds in early stage drug discovery
Ole Pless, DE-Hamburg
15 min   Replacing animal testing by genotoxicity and carcinogenic cell transformation assessment using a tissue regenerating cell line from fish with GFP-labelled histones
Petra Stahlschmidt-Allner, DE-Aarbergen
15 min   A stem cell based metabolic activation system – Potential for replacing rat liver S9 fraction
Cristiano F. Lerche
, DE-Aarbergen
6.2 Stem Cells & Reproductive Toxicity (including mEST & hEST) - EST
Friday, 26 August 2016
20 min   Hand1-Luc Embryonic stem cell test (Hand1-Luc EST): A reporter gene assay using engineered mouse ES cells to evaluate embryotoxicity in vitro
Florian Le Coz, JP-Osaka
20 min   Automation-compatible EST assay
Simon Ströbel, CH-Schlieren
20 min   Prediction of relative developmental toxicity of antifungal compounds using the ES-D3 cell differentiation assay, combined with the BeWo transport model
Hequn Li, UK-Sharnbrook
15 min   Tests for the safety evaluation of a Chinese herbal medicine formula used in the treatment of atopic dermatitis
Lucia Lu Li, CN-Hangzhou
15 min   Good Cell Culture Practice for stem cells, stem-cell-derived models and organ-on-chip models
Mardas Daneshian, DE-Konstanz
7.1 Refinement & Welfare: Culture of Care & Best Practice Approaches
Thursday, 25 August 2016
15 min   Implementation of 3Rs for livestock animals in bioscientific research-rationale and objectives of the newly established expert working group – LaNiV
Fabienne Ferrara, DE-Berlin
15 min   Group housing of rats and rabbits - Thinking out of the box
Kerstin Kleinschmidt-Dörr, DE-Darmstadt
15 min   Refinement and reduction strategies in experimental stroke
Christa Thöne-Reineke, DE-Berlin
15 min   The drinking water as application route for pain management in bone-linked mice models – Combining a refinement and a basic research study
Annemarie Lang, DE-Berlin
15 min   Assessing laboratory mouse welfare using animal-based measures
Elin Spangenberg, SE-Uppsala
15 min   Reducing animal numbers by half: A hybrid preparation technique for the simultaneous investigation of histology and broncho-alveolar lavage parameters of the rat lung
Martin Wiemann, DE-Muenster
7.2 Refinement & Welfare: Avoidance of Severe Suffering
Friday, 26 August 2016
20 min   Focus on severe suffering: an update on RSPCA activity to end severe suffering
Elliot Lilley, UK-Horsham
20 min   Systematic reviews of animal studies equal the implementation of the 3Rs
Merel Ritskes-Hoitinga, NL-Nijmegen
20 min   A proposal for a table to support the classification of the overall severity of a proposed project including animal experiments
Norbert Alzmann, DE-Tuebingen
15 min   How to determine severity degrees for genetically altered rodents?
Anne Zintsch, DE-Berlin
15 min   Repeated isoflurane anesthesia in female mice–Assessing the severity of stress
Katharina Hohlbaum, DE-Berlin
paid advertising

Banner Epithelix

8.1 Replacement of Animals in Research & Use of Non-Animal Methods and Technologies - NEW Non-Animal Methods
Wednesday, 24 August 2016
15 min   Replacement and Non-Animal Methods: The importance to be the change
Candida Nastrucci
, IT-Rome
15 min   The process of isolation and characterisation of HUIEC - Human Intestinal Epithelial Cell Line
Lidija Gradišnik, SL-Slovenia
15 min   Intestinal organoids: Functional studies on nutrient and drug transport, hormone secretion and intracellular signaling
Tamara Zietek, DE-Munich
15 min    Replacement of goat xenobiotic metabolism studies beyond OCED 503 by use of rumen simulation technique (RUSITEC)
Barbara Birk, DE-Ludwigshafen
15 min   Impact of New Technologies on Malignant Tumor Management and Therapy
Lukas Kenner, AT-Vienna
15 min   Three Rs in endocrine disruptor assessment – Refining sampling, reducing numbers of tested animals and replacing in vivo testing
Reinhard Möller, DE-Aarbergen
8.2 Replacement of Animals in Research & Use of non-Animal Methods and Technologies - Serum Free Media
Friday, 26 August 2016

20 min   Serum-free media and serum alternatives
Jan van der Valk, NL-Utrecht
20 min   Towards the replacement of fetal bovine serum in cell culture applications
Christopher Fassbender, UK-London
20 min   A fetal bovine serum free cytotoxicity test following ISO 10993-5
Joachim Wiest, DE-Munich
15 min   IONOSENSE POC: Integration of OECTs with live cells an a 12-well plate for in vitro diagnostics,
Aimie Pavia, FR-Gardanne
9.1 Predictive Toxicology - QSAR & Testing Strategies
Thursday, 25 August 2016
20 min   OECD projects on Integrated Approaches to Testing and Assessment (IATA): a combination of mechanistic information and alternative methods to improve predictive toxicology
Magdalini Sachana, FR-Paris
20 min   EuroMix: using (Q)SARs, TTC, molecular docking simulation and read across as a first tier in mixture toxicity risk assessment
Emiel Rorije, NL-Bilthoven
20 min   A decision-making framework for the grouping and testing
Josje Arts, NL-Arnhem
15 min   A High Accuracy QSAR based on rabbit data to predict the human skin and eye irritation potential of individual constituents and mixtures
Faizan Sahigara, FR-L’Isle D’Abeau
15 min   Computational profiling as a proxy for drug hazard prediction in pharmaceutical research
Friedemann Schmidt, DE-Frankfurt
9.2 Predictive Toxicology - Read Across
Friday, 26 August 2016
20 min   The use of metabolomics in vivo as read across tool: a case study with phenoxy carboxylic acid herbicides
Hennicke Kamp, DE-Ludwigshafen
20 min   Supporting evidence in read across approaches: potential and limitations of new approaches and methodologies
Eric Stilgenbauer
, FI-Helsinki
20 min   Improving confidence in read across: A case study for the oral repeated dose toxicity of β-Olefinic alcohols
Mark Cronin, UK-Liverpool
15 min   Simulating chemical kinetics and dynamics for the prediction of toxicity
Alicia Paini, IT-Ispra
15 min   New possibilities in mathematical toxicology
Marko Raseta, UK-York
paid advertising

Banner MatTek

10.1 Toxicology I - Systemic Toxicity & Environmental Toxicity
Wednesday, 24 August 2016
20 min   EPAA contributions in the area of ADME and carcinogenicity testing
Renate Weissenhorn, BE-Brussels
20 min   Exposure-Based Chemical Safety Assessment Workflow Integrating Alternative Methods: An Ab Initio Case Study for Repeated-Dose Toxicity 
Andrea-Nicole Richarz, IT-Ispra
20 min   Perspectives to use the fish embryo test for applications beyond acute toxicity prediction – chronic fish toxicity, endocrine disruption and developmental toxicity
Stefan Scholz, DE-Leipzig
15 min   Human or mouse fibroblasts for assessing acute toxicity? 
Tuula Heinonen, FI-Tampere
15 min   A medium-throughput method for the analysis of (combinatorial) endocrine effects using the nematode C. elegans
Silvia Vogl, DE-Berlin
10.2 Toxicology I - Inhalation Toxicity
Friday, 26 August 2016

15 min   Evaluation of reconstituted human bronchial epithelium (MucilAir™) suitability for repeated dose testing
Samuel Constant, CH-Plan-les-Ouates
15 min   Metaplastic phenotype in human primary bronchiolar epithelial cells after repeated exposure to mainstream cigarette smoke at the air-liquid interface
Michaela Aufderheide, DE-Hannover
15 min   Establishment and charakterization of a lung/liver organ-on-a-chip model. Phase 1: Model charakterization
David Bovard, CH-Neuchâtel
15 min   Development of an in vitro inhalation toxicity test with potential regulatory applicability
Anna Maione, US-Ashland MA
15 min   Collaborative industry efforts to optimize and standardize in vitro methods suitable for tobacco regulatory science
Erin Hill, US-Gaithersburg MD
15 min   Novel Aerosol exposure devices for in-vitro toxicity testing at the air/liquid interface
Tobias Krebs, DE-Waldkirch
11.1 Toxicology II - Skin Sensitization, Phototoxicity
Friday, 26 August 2016

20 min   Assessment of pre- and pro-haptens using non-animal test methods for skin sensitization
Britta Wareing, DE-Ludwigshafen
20 min   Extending the limits of the hCLAT assay – test of the sensitization potential of oxidative hair dyes
Karsten Mewes, DE-Duesseldorf
20 min   GARD – the future of sensitization testing using a genomics-based platform
Anki Malmborg Hager, SE-Lund
15 min   ITS for skin sensitization potential – 1 out of 2 or 2 out of 3?
David Roberts, UK-Liverpool
15 min   An improved reactive oxygen species assay for photosafety assessment of chemicals with limited aqueous solubility
Yoshiki Seto, JP-Shizuoka
11.2 Toxicology II - Bio-barriers & Novel Testing Concepts
Friday, 26 August 2016

20 min   Cellular and non-cellular elements of the pulmonary air-blood barrier
Claus-Michael Lehr, DE-Saarbruecken
20 min   BioVaSc-TERM - a platform technology to engineer human barrier models
Angela Rossi, DE-Wuerzburg
15 min    The novel ToxTracker reporter system provides mechanistic insight into the genotoxic properties of compounds and materials
Giel Hendriks, NL-Leiden
15 min   Integration of conducting polymer devices with 3D human tissue models for in vitro toxicology testing
Magali Ferro, FR-Gardanne
20 min   If non-animal alternative tests are accepted by regulatory agencies, will industry use them?
Rodger Curren, US-Gaithersburg MD
paid advertising

Banner IvTech

12 Efficacy of Drugs, Biologiocals & Vaccines
Thursday, 25 August 2016

20 min   Towards global harmonisation of 3Rs in biologicals
Katrin Schutte, BE-Brussels
20 min   The “BINACLE” (binding and cleavage) assay allows in vitro determination of botulinum and tetanus neurotoxin activity
Heike Behrensdorf-Nicol, DE-Langen
20 min   G-protein based ELISA as a potency test for human rabies vaccines
Martine Chabaud-Riou, FR-Marcy l'Etoile
15 min   Development, optimization and validation of an in vitro skin irritation test for medical devices using the reconstructed human tissue model Epiderm
Helena Kandarova, SK-Bratislava
15 min   Animal Friendly Affinity Reagents (AFAs): making animal immunisation obsolete
Alison Gray, FR-Morzine
13.1 Disease Models in vitro versus in vivo - Lung Infections
Thursday, 25 August 2016

20 min   Modeling severe infection in human lung tissue
Katja Zscheppang, DE-Berlin
20 min   The use of in vitro human airway epithelia for the development of novel antivirals
Samuel Constant, CH-Plan-les-Ouates
20 min   Novel cystic fibrosis in vitro model for safety and efficacy testing of new drug delivery systems against chronic Pseudomonas aeruginosa infections
Jenny Juntke, DE-Saarbruecken
15 min   Transient receptor potential (TRP) ion channels activation induce increased bronchoconstriction in passive sensitized vital human ex vivo precision-cut lung slices
Susann Dehmel, DE-Hannover
15 min    Modeling fungal infections within a three-dimensional perfused respiratory system
Doris Wilflingseder, AT-Innsbruck
13.2 Disease Models in vitro versus in vivo - Skin & ex vivo Tissues
Wednesday, 24 August 2016
20 min    Inflammatory skin disease models
Sarah Hedtrich, DE-Berlin
20 min    An inflammatory, filaggrin-deficient skin model demonstrates hallmarks of atopic dermatitis in vitro
Stefan Hönzke, DE-Berlin
20 min    Novel perspectives for in vitro models of human skin wounds
Maike Windbergs, DE-Saarbrücken
15 min    Fast and label-free tracking of cell behavior in non-animal models
Karin Schütze, DE-Bernried
15 min    Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis
Peter Valent, AT-Vienna
13.3 Disease Models in vitro versus in vivo - Other Organs
Friday, 26 August 2016

20 min    A human neuronal in vitro model for application in biomedical research and in pharmacological and toxicological investigations
Stefan Schildknecht, DE-Konstanz
20 min    3D in vitro tissue models for infection studies with human pathogens
Matthias Schweinlin, DE-Wuerzburg
20 min   Retinal organotypic cultures as disease model for ophthalmic diseases – recently proposed models
Sven Schnichels, DE-Tuebingen
15 min    Analysis of a novel ex vivo organ model to simulate neurodegeneration in retina
Stephanie Joachim, DE-Bochum
15 min   Recent developments of disease and human in vitro models of the blood-brain barrier
Winfried Neuhaus, AT-Vienna
13.4 Disease Models in vitro versus in vivo - Using Data Bases & Information Tools
Friday, 26 August 2016
25 min    Defining the optimal animal model for translational research using gene set enrichment analysis
Matthias Steinfath, DE-Berlin
25 min    Modernizing law and policy to support innovation in preclinical pharmaceutical testing in the United States
Elizabeth Baker, US-Washington
25 min    From bedside to bench – adding human context to in vitro models
Brigitte Landesmann, IT-Ispra
14.1 3Rs in Education and Academia - Academia
Wednesday, 24 August 2016

25 min   BB3R – educating the next generation of scientists
Monika Schäfer-Korting, DE-Berlin
20 min   ReThink3R – innovation strategies for young scientists – Report of the first workshop
Annemarie Lang, DE-Berlin
15 min   CAAT Academy: From inception to launching
Francois Busquet, BE-Ixelles
15 min   A Course in Replacement Alternatives: To give the good example
Candida Nastrucci, IT-Rome
15 min   Improving transparency on quality and translatability of animal studies using new science driven approach
Judith van Luijk, NL-Nijmegen
14.2 3Rs in Education and Academia - Education
Friday, 26 August 2016

20 min   Teaching practical applications of animal welfare – a review over 10 years of the FELASA B-Course in Vienna
Christiane Winding, AT-Vienna
20 min    Education and Training Platform for Laboratory Animal Science (ETPLAS)
Jan van der Valk, NL-Utrecht
20 min    Development and establishment of an interdisciplinary international master program for laboratory animal science (MLAS): a contribution to the 3R principles
Julia Steitz, DE-Aachen
15 min    Advanced training course for veterinarians to qualify for Animal Welfare Officer
Christa Thöne-Reineke, DE-Berlin
15 min    Establishment of an education program that meets the needs of researchers and animals
Jan Baumgart, DE-Mainz
15.1 Young Scientists Lectures I
Saturday, 27 August 2016
15 min   The use of human (non- 3D equivalent) skin assays (SkimuneTM) for the detection of adverse reactions, potency and efficacy
Ana Ribeiro, UK-Newcastle
15 min   An in vitro system to predict the pro-fibrotic potential of carbon nanotubes in the lung
Hana Barosova
, CH-Fribourg
15 min   Use of human derived liver cell lines for the detection of genotoxic carcinogens
Monika Waldherr, AT-Vienna
15 min   Chronologically-aged fibroblasts significantly alter the morphology of reconstructed human skin
Christian Hausmann, DE-Berlin
15 min   Three dimensional cell culture model for toxicity and efficacy tests
Karolin Fröhlich, DE-Jena
15 min   Development of an innovative moving interface for an in vitro model of the epithelial intestinal barrier
Joana Costa, IT-Massarosa
15 min   Label-free monitoring of HepG2 spheroids – a platform for automated liver toxicity screening
Sebastian Eggert, DE-Munich
15.2 Young Scientists Lectures II
Saturday, 27 August 2016
15 min   Characterization of reconstructed human skin containing Langerhans cells to monitor molecular events in skin sensitization
Gerrit Müller, DE-Berlin
15 min   A novel 3D in vitro model of the deep lung in both healthy and diseased state for screening of safety and efficacy of pulmonary (nano)medicines
Remi Hendrix, DE-Saarbruecken
15 min   Effects of anti-tumor drugs bevacizumab and cisplatin on cancer cell invaded human ex vivo lung tissue in an organotypic model as an alternative to animal experiments
Sebastian Konzok, DE-Hannover
15 min   Safety assessment in EU-substance law: An open door for alternative methods
Lena Hehemann, CH-Fribourg
15 min   Litter loss as a neglected welfare problem?
Charlotte S. Leidinger, DE-Mainz
15 min   Assessment of Hen’s Egg Test Chorioallantoic Membrane (HET-CAM) for screening of anticancer activities of drugs
Mahmoud Galal, EG-Cairo
R1 Round Table I - "Building a career in the 3Rs area: successful biotech SMEs" (plenary)
Wednesday, 24 August 2016

R2 Round Table II - Implementing the concept of "Integrated Approaches to Testing and Assessment (IATA)" into international regulatory testing (plenary)
Thursday, 25 August 2016

P1 Poster Session I
Thursday, 25 August 2016

    Survey of the posters with presence of the authors.
The titles and authors of this poster session I will be published separately.
All posters will be present during all days of the congress.
P2 Poster Session II
Friday, 26 August 2016

    Survey of the posters with presence of the authors.
The titles and authors of this poster session II will be published separately.
All posters will be present during all days of the congress.